Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis
Arthritis Research & Therapy volume 8, Article number: R91 (2006)
IL-10 is a Th2 cytokine important for inhibiting cell-mediated immunity while promoting humoral responses. Human IL-10 (hIL-10) has anti-inflammatory, immunosuppressive as well as immunostimulatory characteristics, whereas viral IL-10 (vIL-10), a homologue of hIL-10 encoded by Epstein Barr virus (EBV), lacks several immunostimulatory functions. The immunostimulatory characteristic of hIL-10 has been attributed to a single amino acid, isoleucine at position 87, which in vIL-10 is alanine. A mutant hIL-10 in which isoleucine has been substituted (mut.hIL-10) is biologically active with only immunosuppressive, but not immunostimulatory, functions, making it a potentially superior therapeutic for inflammatory diseases. To compare the efficacy of mut.hIL-10 with hIL-10 and vIL-10 in blocking the progression of rheumatoid arthritis, we used replication defective adenoviral vectors to deliver intra-articularly the gene encoding hIL-10, vIL-10 or mut.hIL-10 to antigen-induced arthritic (AIA) knee joints in rabbits. Intra-articular expression of hIL-10, vIL-10, and mut.hIL-10 resulted in significant improvement of the pathology in the treated joints to similar levels. These observed changes included a significant reduction in intra-articular leukocytosis and the degree of synovitis, as well as normalization of cartilage matrix metabolism. Our results suggest that hIL-10, vIL-10, and mut.hIL-10 are all equally therapeutic in the rabbit AIA model for treating disease pathology.
Rheumatoid arthritis (RA) is a debilitating, autoimmune disorder characterized by chronic erosive inflammation of the joints with invasive proliferation of synovial cells into the articular cartilage and attendant bone destruction. Pro-inflammatory cytokines, particularly tumor necrosis factor (TNF)-α, and IL-1 are thought to be important mediators that drive the pathophysiology of RA [1–4]. Considerable progress has been reported with the use of biological agents that mediate the pathogenesis of RA, including interleukin-1 receptor antagonist (IL-1Ra), antibodies to IL-1 and TNF-α, and soluble TNF-α receptors [5–10]. In particular, sTNF-R (Enbrel), anti-TNF antibody (Remicade), and IL-1Ra (Kinaret) are commercially available. Unfortunately, these protein-based biological agents have a short half-life, requiring weekly subcutaneous or intravenous delivery. Conversely, intra-articular transfer of the genes encoding immunomodulatory agents is an effective approach to achieve high, localized and sustained levels following a single treatment. Several studies in different animal models of RA clearly show that in vivo gene delivery to one diseased joint is highly effective in ameliorating disease not only in that joint, but in the contralateral joints as well [11–13].
One cytokine that has been of interest as a therapeutic for RA is IL-10. It is a key cytokine found in the human immune response that inhibits cell-mediated immunity and inflammation while promoting humoral responses . It is a 35 kDa non-covalent homodimer produced by macrophages, B-lymphocytes and Th2 cells, and is a potent inhibitor of Th1 cytokines . This activity accounts for its initial designation as a cytokine synthesis inhibition factor (CSIF) .
The actions of IL-10 are diverse in that IL-10 can be anti-inflammatory, immunosuppressive or immunostimulatory, depending upon the target cell. However, the principal function of IL-10 appears to be anti-inflammatory, limiting and eventually terminating inflammatory responses by inhibiting synthesis of monocyte and macrophage derived pro-inflammatory cytokines [15–19]. IL-10 also has the ability to inhibit the antigen-presenting function of monocytes/macrophages and dendritic cells through the down-regulation of MHC class II molecules and the co-stimulatory molecules B7 and intercellular adhesion molecule-1 (ICAM-1), classifying it as an immunosuppressive cytokine [20–24]. In addition to these activities, IL-10 has some immunostimulatory properties; it regulates growth and/or differentiation of B cells, natural killer cells, cytotoxic and helper T cells, mast cells, granulocytes, dendritic cells, keratinocytes, and endothelial cells. IL-10 plays a key role in differentiation and function of the regulatory T cell [25, 26].
Human IL-10 (hIL-10) exhibits 73% homology with murine IL-10 (mIL-10) and 84% with the open reading frame of the Epstein-Barr virus (EBV), initially known as BCRF1 or now termed as viral IL-10 (vIL-10) . vIL-10 shares many of the anti-inflammatory properties of mIL-10 and hIL-10, but lacks their immunostimulatory properties [24, 25]. Isoleucine at position 87 of murine and human IL-10 is crucial for the immunostimulatory function. This amino acid in viral IL-10 is alanine. Studies have shown that by substituting isoleucine with alanine at position 87 in hIL-10, the immunostimulatory response could be abrogated, leaving the mutant human IL-10 (mut.hIL-10) biologically active with only immunosuppressive activity and receptor species specificity . Various studies of inflammatory situations, in mouse tumor models, cardiac allograft experiments, and endotoxemic models, have all suggested a potential superiority of vIL-10 over hIL-10 as an immunosuppressive agent [29–31]. vIL-10 has also been tested in the antigen induced arthritis (AIA) rabbit model and the collagen induced arthritis mouse model and shown to confer a significant therapeutic effect [11, 12, 32, 33].
In this study, we used the rabbit AIA model to compare directly the therapeutic efficacy of hIL-10, vIL-10, and mut.hIL-10, encoded by genes delivered intra-articularly in vivo by adenoviral vector. We demonstrate that expression of hIL-10, vIL-10 or mut.hIL-10 in the rabbit joints were similarly effective not only in preventing the progression of the disease by blocking leukocytic infiltration, but also reducing the degree of synovitis, as well as normalizing cartilage metabolism. These results suggest that the three variants of IL-10, hIL-10, vIL-10, and mut.hIL-10, are all equally therapeutic when delivered locally in the rabbit experimental arthritis model.
Materials and methods
The recombinant vectors used in this study were E1/E3 deleted replication-defective type 5 adenoviruses . The cDNA encoding either hIL-10, vIL-10, mut.hIL-10 or enhanced green fluorescent protein (eGFP) was inserted into the E1 region with gene expression driven by the early promoter of the human cytomegalovirus. High titer recombinant adenoviruses (Ad.hIL-10, Ad.vIL-10, Ad.mut.hIL-10, and Ad.eGFP) were generated as described previously  by Cre-Lox driven homologous recombination and permissive replication in CRE8 cells, a 293 cell-line (ATCC, MD) that expresses Cre recombinase. Viral titers were determined by optical density at 260 nm (OD260) where 1 OD unit = 1012 viral particles .
Female New Zealand White rabbits, weighing approximately 5 to 6 lbs each, were purchased from Myrtles Rabbitry (Thompson Station, TN, USA) and housed in the Central Animal Facility at the University of Pittsburgh. The animals were acclimatized for three days before experimentation and were fed chow ad libitum and water. All animal experiments were conducted in accordance with NIH standards of animal care and the animal protocol used for this study was approved by the animal ethics committee of the University of Pittsburgh.
The rabbits were sensitized by a series of two intradermal injections of 5 mg of chick ovalbumin (OVA; Sigma, St. Louis, MO, USA), emulsified in Freund's complete adjuvant (Pierce, Rockford, IL, USA) and Freund's incomplete adjuvant (Pierce) respectively, given 10 days apart . Acute monoarticular arthritis was induced in both knee joints two weeks after the booster shot by intra-articular injection of OVA dissolved in 0.5 ml saline.
Twenty-four hours post-initiation of AIA, 5 × 109 particles of replication-defective adenovirus encoding either hIL-10, vIL-10, mut.hIL-10 or eGFP (control) was suspended in 0.2 ml sterile saline and injected into the joint space via the patellar tendon.
On days 3 and 7 post adenoviral delivery, the rabbit knee joints were lavaged by the injection of 1 ml of Gey's balanced salt solution (Gibco-BRL, Grand Island, NY, USA) into the joint space via the patellar tendon. After manipulation of the joint, the needle was reinserted and the fluid aspirated. Leukocytes suspended in the recovered lavage fluid were counted using a hemocytometer. Levels of IL-10 in recovered lavage fluids and sera were measured using a cytokine ELISA kit (Pierce Endogen, Rockford, IL, USA).
To quantify the glycosaminoglycans (GAGs) released into the joint space as a result of cartilage proteoglycan breakdown, the lavage fluid from days 3 and 7 were first centrifuged at 14,000 × g for 10 minutes to get rid of all the debris, and the supernatant recovered. Aliquots (100 μl) of this supernatant were treated with papain to enzymatically cleave the proteins. Then, 20 μl of papain suspension (Type III, 19 U/mg protein; Sigma) was added to 1 ml of buffer containing 10 mM sodium EDTA and 0.4 M sodium acetate, pH 5.2. This papain solution (100 μl) was added to 100 μl of lavage fluid supernatant and incubated overnight at 60°C. Papain was then inactivated by iodoacetic acid (Sigma) to a final concentration of 4 mM. The samples were centrifuged at 14,000 × g for 10 minutes, and the supernatant transferred to fresh tubes; 2 U of hyaluronate lysase (Sigma) was added and the samples incubated at 37°C overnight. Sulfated GAG concentrations were measured as previously described  by a colorimetric dye binding assay using 1,9-dimethylmethylene blue reagent.
To measure the rate of proteoglycan synthesis, the harvested knees were dissected, and fragments of articular cartilage were shaved from the femoral condyles. Cartilage fragments weighing approximately 30 to 40 mg were incubated in 1 ml Newman and Tyell serum-free media (Gibco-BRL) with 40 μCi 35SO42- for 24 hours at 37°C. At the end of this incubation, the media was recovered and stored at -20°C. The cartilage fragments were subsequently incubated in 1 ml 0.5 M NaOH at 4°C with gentle agitation for 24 hours to extract the proteoglycans. At the end of this incubation, the media was recovered and stored at -20°C. Unincorporated 35SO42- from media was chromatographically separated using PD-10 columns (Pharmacia, Piscataway, NJ, USA), and radiolabeled GAGs released into the culture media or recovered from the alkaline treatment were quantified by scintillation counting, as described previously .
On day 7, the rabbits were euthanized by Beuthanasia-D (Schering Plough Animal Health Corp., Union, NJ, USA) overdose, and the knee joints collected. Synovial capsules were immersion-fixed in 10% buffered formalin for several days. The fixed tissues were then dehydrated in a gradient of alcohols, paraffin embedded, sectioned at 5 μm, mounted on glass slides, and then stained using hematoxylin and eosin. Sections were examined by light microscopy at 20× magnification.
Data were analyzed using the Microsoft Excel graphing and statistical program. The Student's t test assuming unequal variances were performed to determine significant differences between groups. P < 0.05 was considered statistically significant.
Expression of hIL-10, vIL-10, and mut.hIL-10 after intra-articular injection of recombinant adenovirus into the rabbit knee
To compare the therapeutic effects of hIL-10, vIL-10, and mut.hIL-10 in a rabbit knee model of antigen induced arthritis, disease was induced by intra-articular injection of OVA into the knees of OVA immunized rabbits. Twenty-four hours post induction, 5 × 109 particles of first generation Ad.5-based vectors encoding either hIL-10, vIL-10, mut.hIL-10 or eGFP under the regulation of the cytomegalovirus enhancer/promoter were injected intra-articularly into rabbit knees. A naïve control group of rabbits was also included. Lavages were performed using saline on days 3 and 7 after adenoviral delivery, and the levels of hIL-10, vIL-10, and mut.hIL-10 in the recovered lavage fluids determined using a cytokine ELISA. ELISA measurements showed similar levels of expression of hIL-10, vIL-10, and mut.hIL-10 (Figure 1). IL-10 was not detected in sera (data not shown) of any of the treated animals or in the lavage fluids of knees that received Ad.eGFP.
Effect of hIL-10, vIL-10, and mut.hIL-10 expression on joint inflammation
Leukocytosis is one quantitative measure of inflammation. To test and compare the ability of hIL-10, vIL-10, and mut.hIL-10 to inhibit inflammation in the inflamed rabbit knees, the number of leukocytes in the lavage fluids at days 3 and 7 were determined. The arthritic knee joints that received Ad.eGFP exhibited severe joint inflammation with a mean level of infiltrating leukocytes exceeding 15.16 × 106 cells per ml of lavage fluid at day 3, and exceeding 14.86 × 106 cells per ml of lavage fluid at day 7 (Figure 2). In comparison, lavage fluid from joints that received Ad.hIL-10 showed an average of 6.14 × 106 leukocytic cells per ml, a 60% reduction on day 3 with the number of cells reducing to 1.92 × 106 per ml, an 87% reduction by day 7. Similarly, leukocytic infiltrates from Ad.vIL-10 and Ad.mut.hIL-10 knees showed 51% and 55% reduction on day 3, and 72% and 93% reduction by day 7, respectively. The control, naïve rabbit knees showed an average of 104 leukocytes per ml.
Effect of hIL-10, vIL-10, and mut.hIL-10 expression on cartilage matrix metabolism
GAG release into the synovial fluid is used as an index to determine cartilage matrix degradation. As shown in Figure 3a, hIL-10, vIL-10, and mut.hIL-10 repressed proteoglycan breakdown equally. The arthritic control knees receiving Ad.eGFP had very high levels of GAGs released into their lavage fluids whereas, on day 3, the Ad.hIL-10, vIL-10 or mut.hIL-10 treated knees showed a significant reduction of approximately 30%. By day 7, this reduction had further increased to approximately 46%, a level that was similar to naïve rabbit knees.
GAG synthesis is another parameter of cartilage matrix metabolism. To determine and compare the ability of hIL-10, vIL-10, and mut.hIL-10 to synthesize GAGs, 35S incorporation into proteoglycans of articular cartilage from femoral condyles was measured at day 7. GAG synthesis in arthritic, Ad.eGFP treated control knees was 61% of naïve joints (Figure 3b). In contrast, the level of GAG synthesis in knees that received Ad.hIL-10 was 99.5%, Ad.vIL-10 was 97%, and Ad.mut.hIL-10 was 82% that of naïve control knees.
Histological analysis was done on tissues obtained from naïve and AIA rabbit knee joints (Figure 4). Compared to the naïve rabbit knee tissue (Figure 4a), sections from arthritic control knees that received Ad.eGFP appeared to have acute synovitis, typical of AIA (Figure 4b). The synovium was highly thickened, fibrous, hypertrophic, and hyperplasic due to excessive proliferation of synovial cells and infiltration by mononuclear leukocytes. Tissues obtained from AIA rabbit knees treated with Ad.hIL-10, Ad.vIL-10 or mut.hIL-10 (Figure 4c–e) were all more or less identical to the naïve control tissue, suggesting that Ad.hIL-10, Ad.vIL-10, and Ad.mut.hIL-10 were fairly efficacious in halting the progression of disease.
IL-10 is an important multifunctional cytokine that mediates the inflammatory response. The human homologue is immunostimulatory, immunosuppressive or anti-inflammatory depending upon the target tissue , whereas the viral homologue appears to be predominantly immunosuppressive and anti-inflammatory . The biologically active mut.hIL-10 with a substituted alanine at position 87 has only immunosuppressive and anti-inflammatory capabilities similar to vIL-10 . Experiments have shown that mut.hIL-10, like vIL-10, prevents mast cell proliferation and prolongs allograft survival in mice [28, 30].
Previous studies have examined the effects of vIL-10 in the AIA rabbit model as well as the collagen induced arthritis mouse model showing efficacious results for treatment [11, 12, 32, 33]. However, the cellular form of IL-10 has not been examined in the AIA model, and vIL-10 and mut.hIL-10 not compared in either rabbit or rodent models. In addition, it has been speculated that since mut.hIL-10 only has immunosuppressive and anti-inflammatory characteristics, it might be a superior cytokine for therapy of inflammatory diseases, as it would be less antigenic than vIL-10.
In this report, we have examined and compared the therapeutic potential of hIL-10, vIL-10, and mut.hIL10 in the AIA rabbit model. We have demonstrated that local adenovirus-mediated intra-articular gene transfer of hIL-10, vIL-10 or mut.hIL-10 in the rabbit knees resulted in significant improvements in several pathologies associated with the disease. A considerable decrease in the number of intra-articular infiltrating leukocytes as well as the degree of synovitis in the knee joints was observed. In addition, these cytokines displayed not only a chondroprotective effect in blocking cartilage matrix breakdown but also a chondrogenic effect in maintaining new cartilage matrix synthesis. Interestingly, our data suggest that hIL-10 effectively blocked the progression of the disease in the knees of the AIA rabbits despite its immunostimulatory function. Furthermore, the mutant form of hIL-10 was as effective as vIL-10 in inhibiting the AIA in rabbits, but not more effective than wild-type IL-10.
A previous study from our group has shown that TNF-α levels in rabbit arthritic knees were reduced by vIL-10 treatment . Additional studies have shown vIL-10 to be able to inhibit the production of pro-inflammatory cytokines such as TNF-α and T cell growth factors, as well as block antigen presentation on macrophages and dendritic cells [20–24]. Thus, it is likely that the therapeutic effects of hIL-10 and mut.hIL-10 are also due partially to the suppression of TNF-α, or blockage of antigen presentation on antigen-presenting cells.
The application of gene therapy represents a novel approach for the treatment of RA, overcoming obstacles of protein delivery while providing a sustainable high efficacy and greater safety. Multiple studies in different animal models with direct viral gene transfer of therapeutic agents provide proof supporting the use of gene therapy in arthritis [9–13, 32, 33], and a recent phase I clinical trial using IL-1Ra by ex vivo gene transfer to arthritic joints was also successfully completed [40, 41]. Systemic non-viral delivery methods, such as administration of engineered syngeneic fibroblasts , and intranasal delivery of plasmid DNA  also show promise.
Although shown in several experimental animal models to be an effective therapeutic for arthritis [11, 12, 32, 33], vIL-10 has not been considered for clinical gene therapy use. It is a foreign protein and would consequently generate a neutralizing immune response undermining its potential as a therapeutic. However, hIL-10 and presumably mut.hIL-10 would be recognized as self and would escape the immune response. Both these cytokines have shown significant therapeutic efficacy in our study using the AIA rabbit model and could hence have considerable potential for development of clinical gene therapy approaches for RA.
In this report, we demonstrate by adenoviral-mediated intra-articular gene transfer to the rabbit knee that hIL-10, vIL-10, and mut.hIL-10 are all similarly effective in blocking the progression of antigen induced arthritis. In particular, the three forms of IL-10 were all successful in reducing intra-articular leukocytosis and the degree of synovitis, as well as normalizing cartilage matrix metabolism. These results demonstrate that hIL-10 and mut.hIL-10, which are non-immunogenic compared to vIL-10, would be as efficacious as vIL-10 in treating arthritis pathologies following intra-articular gene transfer.
= antigen-induced arthritis
= enzyme-linked immunosorbent assay
= human IL-10
= interleukin-1 receptor antagonist
= mutant human IL-10
= rheumatoid arthritis
= tumor necrosis factor
= viral IL-10.
DiGiovine FS, Nuki G, Duff GW: Tumor necrosis factor in synovial exudates. Ann Rheum Dis. 1988, 47: 768-772.
Miyasaka N, Sato K, Goto M, Sasano M, Nutsuyama M, Inoue K, Nishiota K: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum. 1988, 31: 480-486.
Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum. 1992, 35: 1160-1169.
Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 151-160.
Lewthwaite J, Blake SM, Hardingham TM, Warden PJ, Henderson B: The effect of recombinant human IL-10 receptor antagonist on the induction of antigen induced arthritis in the rabbit. J Rheumatol. 1994, 21: 467-472.
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301.
Bresnihan B, Alvaro-Garcia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al: Treatment of rheumatoid arthritis with recombinant human interelukin-1 receptor antagonist. Arthritis Rheum. 1998, 41: 2196-2204. 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2.
Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumor necrosis factor (cA2) in patients with rheumatoid arthritis. Lancet. 1994, 344: 1125-1127. 10.1016/S0140-6736(94)90632-7.
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor [alpha](cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 244: 1105-1110. 10.1016/S0140-6736(94)90628-9.
Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larson scores. Arthritis Rheum. 2000, 43: 1001-1009. 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P.
Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z, Evans CH, Robbins PD: Direct adenoviral gene transfer of vIL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol. 1999, 163: 2202-2208.
Whalen JD, Lechman ER, Carlos CA, Weiss K, Kovesdi I, Robbins PD, Evans CH: Adenoviral transfer of the vIL-10 gene peri-articularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol. 1999, 162: 3625-3632.
Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, Robbins PD: Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA. 1998, 95: 4613-4618. 10.1073/pnas.95.8.4613.
Burdin N, Rousset F, Banchereau J: B-Cell-Derived IL-10: Production and Function. Methods. 1997, 11: 98-111. 10.1006/meth.1996.0393.
Moore KW, de Waal Malefyt R, Coffman RL, O'Gara A: Interleukin-10 and the Interleukin-10 receptor. Annu Rev Immunol. 2001, 19: 638-765. 10.1146/annurev.immunol.19.1.683.
Lalani I, Bhoi K, Ahmed AF: Interleukin-10: Biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol. 1997, 79: 469-483.
Howard M, O'Garra A: Biological properties of interleukin-10. Immunol Today. 1992, 13: 198-200. 10.1016/0167-5699(92)90153-X.
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991, 174: 1209-1220. 10.1084/jem.174.5.1209.
Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin-10. J Ex Med. 1991, 174: 1549-1555. 10.1084/jem.174.6.1549.
de Waal Malefyt R, Haanen J, Spits H, Roncorolo MG, Tevelde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin-10 and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class-II major histocompatibility complex expression. J Exp Med. 1991, 174: 915-924. 10.1084/jem.174.4.915.
Ding L, Linsley PS, Huang LY, Germania RN, Sherach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol. 1993, 151: 1224-1234.
Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, Goldman M: Interleukin-10 inhibits B7 and ICAM-1 expression on human monocytes. Eur J Immunol. 1994, 24: 1007-1009.
Beulens C, Willems F, Delveaux A, Peirard G, Delville JP, Velu T, Goldman M: Interleukin-10 differentially regulates B7-1 (CD80) andB7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol. 1995, 25: 2668-2672.
de Vries JE: Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann Med. 1995, 27: 537-541.
Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M: Interleukin-10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med. 1990, 172: 1625-1631. 10.1084/jem.172.6.1625.
Katsikis P, Chu C-Q, Brennan FM, Maini R, Feldmann M: Immunoregulatory role of interleukin-10 in rheumatoid arthritis. J Exp Med. 1994, 179: 1517-1527. 10.1084/jem.179.5.1517.
Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science. 1990, 248: 1230-1234.
Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg S: A single amino acid determines the immunostimulatory activity of interleukin-10. J Exp Med. 2000, 191: 213-224. 10.1084/jem.191.2.213.
Drazen KE, Wu L, Bullington D, Shaken A: Viral IL-10 gene therapy inhibits TNF-α and IL-1β, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg. 1996, 31: 411-414. 10.1016/S0022-3468(96)90749-6.
Qin L, Chevin KD, Ding Y, Tahara H, Favarro JP, Woodward JE, Suzuki T, Robbins PD, Lotze MY, Bromberg JS: Retrovirus-mediated transfer of vIL-10 gene prolongs murine cardiac allograft survival. J Immunol. 1996, 156: 2316-2323.
Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MY: Viral IL-10 (vIL-10), the human herpes virus 4- cellular IL-10 (cIL-10) homologue, induces local anergy to allogenic and syngenic tumors. J Exp Med. 1995, 102: 477-486. 10.1084/jem.182.2.477.
Ma Y, Thornton S, Duwel LE, Biovin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R: Inhibition of collagen-induced arthritis in mice by vIL-10 gene transfer. J Immunol. 1998, 161: 1516-1524.
Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgenson C: Adenovirus-mediated transfer of vIL-10 gene inhibits murine collagen-induced arthritis. J Immunol. 1998, 160: 5213-5220.
Yeh P, Perricaudet M: Advance in adenoviral vectors: from genetic engineering to their biology. FASEBJ. 1997, 11: 615-623.
Graham FL, Van der Eb AJ: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973, 52: 456-467. 10.1016/0042-6822(73)90341-3.
Mittereder N, March KL, Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996, 70: 7498-7509.
Dumonde DC, Glynn LE: The production of arthritis in rabbits by an immunological reaction to fibrin. Br J Ex Pathol. 1962, 43: 373-382.
Farndale RW, Buttle DJ, Barnette AJ: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochem Biophy Acta. 1986, 883: 173-177.
Taskiran D, Stefanovic-Racic M, Georgescu H, Evans CH: Nitric-oxide mediates suppression of cartilage proteoglycan synthesis by interleukin 1. Biochem Biophys Res Commun. 1994, 200: 142-148. 10.1006/bbrc.1994.1426.
Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, Robbins PD: Clinical trials in the gene therapy of arthritis. Clin Orthop Relat Res. 2000, 379: S300-S307. 10.1097/00003086-200010001-00039.
Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzinigro TA, Vogt M, Elder EM, Whiteside TL, et al: Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA. 2005, 102: 8698-8703. 10.1073/pnas.0502854102.
Bessis N, Cottard V, Saidenberg-Kermanach N, Lemeiter D, Fournier C, Boissier MC: Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J Gene Med. 2002, 4: 300-307. 10.1002/jgm.275.
Woods AM, Thompson SJ, Wooley PH, Panayi G, Klavinskis LS: Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery. Arthritis Rheum. 2005, 52: 3761-3771. 10.1002/art.21473.
We would like to thank Jonathan Bromberg for kindly giving us the mut.hIL-10 cDNA. This work was supported by National Institutes of Health grants AR62225 and DK44935 to PDR.
The University of Pittsburgh has patented gene therapy approaches for treating arthritis. PDR is a Scientific Advisory Board member of a company that has licensed the technology.
AK and ERL performed the construction of the adenoviral vectors and analysis in the rabbit model of AIA and AK wrote the initial draft of the manuscript. JN and ZM assisted in the therapeutic analysis in the rabbit model. PDR conceived of the study and participated in its design and helped to edit the manuscript.
About this article
Cite this article
Keravala, A., Lechman, E.R., Nash, J. et al. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther 8, R91 (2006). https://doi.org/10.1186/ar1960
- Lavage Fluid
- Antigen Induce Arthritis
- Rabbit Knee
- Clinical Gene Therapy